193 related articles for article (PubMed ID: 28488143)
1. Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.
Cabarrou B; Mourey L; Dalenc F; Balardy L; Kanoun D; Roché H; Boher JM; Rougé-Bugat ME; Filleron T
Breast Cancer Res Treat; 2017 Aug; 164(3):505-513. PubMed ID: 28488143
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
4. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.
Brain EG; Mertens C; Girre V; Rousseau F; Blot E; Abadie S; Uwer L; Bourbouloux E; Van Praagh-Doreau I; Mourey L; Kirscher S; Laguerre B; Fourme E; Luneau S; Genève J; Debled M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):160-70. PubMed ID: 21035352
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
Hamberg P; Verweij J; Seynaeve C
Eur J Cancer; 2007 Jul; 43(10):1514-28. PubMed ID: 17482454
[TBL] [Abstract][Full Text] [Related]
6. Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.
Mariano C; Francl M; Pope J; Wong L; Lim HJ; Lohrisch C
Clin Breast Cancer; 2015 Feb; 15(1):73-9. PubMed ID: 25445420
[TBL] [Abstract][Full Text] [Related]
7. Advanced breast cancer: chemotherapy phase III trials that change a standard.
Estevez LG; Tusquets I; Muñoz M; Adrover E; Rovira PS; Seguí MA; Rodríguez CA; Lescure AR; Ruiz M; Alvarez I; Mata JG
Anticancer Drugs; 2007 Aug; 18(7):843-59. PubMed ID: 17581310
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
9. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
12. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
Gouverneur A; Salvo F; Berdaï D; Moore N; Fourrier-Réglat A; Noize P
J Geriatr Oncol; 2018 Jan; 9(1):15-23. PubMed ID: 28844343
[TBL] [Abstract][Full Text] [Related]
13. An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
Conde-Estévez D; Tusquets I; Servitja S; Martínez-García M; Salas E; Albanell J
Anticancer Drugs; 2014 Oct; 25(9):992-7. PubMed ID: 24892723
[TBL] [Abstract][Full Text] [Related]
14. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
15. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
Tkaczuk KH
Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
[TBL] [Abstract][Full Text] [Related]
16. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
17. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of breast cancer in the elderly is not evidence-based].
van de Water W; Bastiaannet E; Liefers GJ
Ned Tijdschr Geneeskd; 2011; 155(42):A3359. PubMed ID: 22027456
[TBL] [Abstract][Full Text] [Related]
19. Strategies for improving quality of life in older patients with metastatic breast cancer.
Kurtz JE; Dufour P
Drugs Aging; 2002; 19(8):605-22. PubMed ID: 12207554
[TBL] [Abstract][Full Text] [Related]
20. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
